The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease
Authors:
- 1 July 2015
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (11) , 1467-1475
Abstract
No abstract availableKeywords
Funding Information
- Amgen Inc
This publication has 26 references indexed in Scilit:
- Onco-NephrologyClinical Journal of the American Society of Nephrology, 2012
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Medical Applications and Toxicities of Gallium CompoundsInternational Journal of Environmental Research and Public Health, 2010
- Bisphosphonate nephrotoxicityKidney International, 2008
- Hypercalcemia Associated with CancerNew England Journal of Medicine, 2005
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Parathyroid hormone-related protein(50–69) and response to pamidronate therapy for tumour-induced hypercalcaemiaEuropean Journal of Cancer and Clinical Oncology, 1991
- Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and boneJournal of Bone and Mineral Research, 1990
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982